Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer

Inclusion Criteria: * Documented colorectal cancer which is EGFR-positive and is metastatic. * Prior irinotecan, alone or in combination, as first-line treatment of metastatic disease. Exclusion Criteria: * A serious uncontrolled medical disorder that, in the opinion of the Investigator, would impair the ability of the subject to receive protocol therapy. * Known dihydropyrimidine dehydrogenase (DPD) deficiency. * Known metastases in the central nervous system. * Symptomatic sensory or peripheral neuropathy. * More than one prior chemotherapy regimen for the treatment of metastatic colorectal cancer. * Prior oxaliplatin therapy. * Prior cetuximab or other therapy which targets the EGF pathway. * Prior chimerized or murine monoclonal antibody therapy.